Clinical trial NCT05961605: COVID-19 Associated With Psoriasis
Official title: Retrospective Clinical Study of COVID-19 Associated With the Condition and Treatment of Patients With Chinese Psoriasis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Psoriasis Patients
COVID-19
Keywords: psoriasis
covid-19
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2023-07-27
Enrollment: 2500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Psoriasis patients registered in the database from January 2018 to November 2022

Brief summary: A retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients.

Detailed description: Based on the patients registered in the psoriasis patient database of each center, the patients were followed up by telephone, and the severity of covid-19 infection, the change of psoriasis condition and the adjustment of treatment methods of psoriasis patients were collected for retrospective analysis.

Eligibility criteria: Inclusion criteria ----

1. No age limit, both male and female are accepted;
2. Psoriasis patients registered in the database;
3. Patients or their families can cooperate to complete the follow-up information survey (questionnaire, telephone, etc.) independently, and ensure the authenticity of the data provided.

Exclusion criteria ----

Patients are thought having conditions which are not appropriated for attending this clinical trial.

Primary outcomes:
measure: The recurrence/exacerbation of psoriasis following SARS-CoV-2 infection
timeFrame: March 15,2023 to May 30,2023
Secondary outcomes:
measure: Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection
timeFrame: March 15,2023 to May 30,2023
Other outcomes:
Locations:
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
state: Chongqing
city: Lanzhou
country: China
facility: The First Hospital of Lanzhou University
state: Gansu
city: Guangzhou
country: China
facility: Dermatology Hospital of Southern Medical University
state: Guangdong
city: Changchun
country: China
facility: The Second Hospital of Jilin University
state: Jilin
city: Dalian
country: China
facility: Dalian Dermatosis Hospital
state: Liaoning
city: Xining
country: China
facility: Xining First People's Hospital
state: Qinghai
city: Xi'an
country: China
facility: Xijing Hospital, The Fourth Military Medical University
state: Shaanxi
city: Shanghai
country: China
facility: Shanghai Skin Disease Hospital, Tongji University School of Medicine
state: Shanghai
city: Shenzhen
country: China
facility: The University of Hong Kong-Shenzhen Hospital
state: Shenzhen
city: Chengdu
country: China
facility: West China Hospital, Sichuan University
state: Sichuan
city: Tianjin
country: China
facility: Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
state: Tianjin
city: Ürümqi
country: China
facility: People's Hospital of Xinjiang Uygur Autonomous Region，Xinjiang Key Laboratory of Dermatology Research
state: Xinjiang
Study officials:
affiliation: Xijing Hospital, The Fourth Military Medical University
name: GANG WANG, M.D.
role: PRINCIPAL_INVESTIGATOR
References: